As part of the collaboration between ATCC and The Michael J. Fox Foundation for Parkinson’s Research (MJFF), ATCC is providing isogenic, CRISPR genome-edited induced pluripotent stem cell lines (iPSCs) with SNCA frameshift mutations. In this second of three interviews, Dr. Brian Shapiro, a Marketing Segment Manager at ATCC, met with Dr. Birgitt Schüle, an Associate Professor in the Department of Pathology at Stanford University School of Medicine, to discuss the development and characterization of these cell models and their potential uses in Parkinson’s disease research.